Article Details
Retrieved on: 2025-01-02 16:26:19
Tags for this article:
Click the tags to see associated articles and topics
Summary
Edwards Lifesciences plays a significant role in the 2024 medtech dealmaking resurgence by selling its critical care group to BD for $4.2 billion, enhancing BD's advanced patient monitoring business and contributing to industry growth.
Article found on: www.medtechdive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here